Nucleic acids—including DNA and RNA—are central to modern biomedical research and medicine. Technologies such as CRISPR gene editing and RNA sequencing are opening new possibilities in cancer immunotherapy, infectious disease diagnostics, rare disease treatment, therapeutic vaccines, genetic therapies and precision medicine.

However, translating nucleic acid technologies into routine clinical practice remains challenging. Researchers need more sensitive and accurate methods to detect low-abundance nucleic acid biomarkers, improved approaches to direct RNA sequencing, and safer, more effective strategies for delivering nucleic acid-based therapeutics in vivo. INT2ACT addresses these needs through interdisciplinary research and doctoral training, helping unlock the full potential of nucleic acids for personalised medicine.